1-4 of 4
Hugo Fernandez, MD
Close
Sort by
Journal Articles

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Janelle Perkins, PharmD, Jongphil Kim, PhD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD, Ernesto Ayala, MD, Lia Perez, MD, Hugo Fernandez, MD, Karen Fancher, PharmD, Cheryl Tate, PharmD, Teresa Field, MD
Journal: Blood
Blood (2009) 114 (22): 3347.
https://doi.org/10.1182/blood.V114.22.3347.3347
Published: 2009
Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine.

Teresa Field, MD, PhD, Melissa Alsina, MD, Ernesto Ayala, MD, Hugo Fernandez, MD, William Janssen, PhD, Mohammed Karfan-Dabaja, MD, Jeffery Lancet, MD, Mafda Melchert, MD, Jyoti Raychaudhuri, MD, Daniel Sullivan, MD, Alan List, MD, Claudio Anasetti, MD, William Poling, PhD, Janelle Perkins, PharmD
Journal: Blood
Blood (2007) 110 (11): 5035.
https://doi.org/10.1182/blood.V110.11.5035.5035
Published: 2007
Journal Articles

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Todd Alekshun, MD, Christine Mcisaac-Simonelli, RN, Mohamed Kharfan-Dabaja, MD, William Dalton, MD, PhD, Benjamin Djulbegovic, MD, Hugo Fernandez, MD, Daniel M. Sullivan, MD, Ernesto Ayala, MD, Teresa L. Field, MD, Dawn Garrett, LPN, William E. Janssen, PhD, Beth Maddox, RN, Lia Perez, MD, Dawn Kettner, PA, Janelle Perkins, PharmD, Jyoti Raychaudhuri, MD, Claudio Anasetii, MD, Melissa Alsina, MD
Journal: Blood
Blood (2007) 110 (11): 5131.
https://doi.org/10.1182/blood.V110.11.5131.5131
Published: 2007
Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD
Journal: Blood
Blood (2007) 110 (11): 943.
https://doi.org/10.1182/blood.V110.11.943.943
Published: 2007